Y-box binding protein 1: A critical target for understanding and treating cardiovascular disease

Zixuan Liu1, Hongjie Wang1, Lei Dai1

  • 1Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China; Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan 430030, Hubei, China.

Cellular Signalling
|April 9, 2025
PubMed

Insights

Cold shock protein Y-box binding protein 1 (YB-1) is crucial in cardiovascular diseases (CVDs), regulating various cellular processes. Understanding YB-1

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Cardiovascular diseases (CVDs) represent a major global health challenge, necessitating innovative treatments.
  • Y-box binding protein 1 (YB-1), a cold shock protein, is a key regulator in pathophysiological processes, including CVDs.
  • YB-1 influences gene expression, RNA processing, translation, and stability, impacting cellular functions.

Purpose of the Study:

  • To comprehensively review the structure, regulation, and functional significance of YB-1 in the context of CVDs.
  • To explore transcriptional, translational, and post-translational regulatory mechanisms of YB-1.
  • To examine upstream signaling pathways, including non-coding RNAs, influencing YB-1 in cardiovascular conditions.

Main Methods:

  • Literature review synthesizing existing research on YB-1 in cardiovascular diseases.
  • Analysis of YB-1's role in inflammation, oxidative stress, cell proliferation, apoptosis, and mitochondrial function.
  • Examination of YB-1's expression patterns and regulatory networks in various CVD models and stages.

Main Results:

  • YB-1 exhibits pleiotropic functions in CVDs, affecting critical cellular pathways.
  • YB-1 regulation is complex and context-dependent, with varied effects across different cell types and disease stages.
  • Upstream signaling, including non-coding RNAs, significantly influences YB-1 expression and function in CVDs.

Conclusions:

  • YB-1 is a multifaceted regulator in cardiovascular diseases with significant therapeutic potential.
  • Further research into YB-1's intricate regulatory mechanisms is warranted for targeted therapeutic development.
  • Targeting YB-1 offers a promising strategy for improving cardiovascular health and managing CVDs.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
280
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
501
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
38
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
394